NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis $3.73 +0.04 (+1.08%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.64▼$3.8350-Day Range$2.61▼$3.7352-Week Range$0.95▼$4.16Volume1.24 million shsAverage Volume1.39 million shsMarket Capitalization$921.95 millionP/E RatioN/ADividend YieldN/APrice Target$6.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nuvation Bio alerts: Email Address Nuvation Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.9% Upside$6.60 Price TargetShort InterestBearish8.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 4 Articles This WeekInsider TradingAcquiring Shares$1.77 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.31) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector485th out of 936 stocksPharmaceutical Preparations Industry223rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvation Bio has only been the subject of 2 research reports in the past 90 days.Read more about Nuvation Bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.73% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Nuvation Bio has recently increased by 14.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVB. Previous Next 3.1 News and Social Media Coverage News SentimentNuvation Bio has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nuvation Bio this week, compared to 1 article on an average week.Search Interest8 people have searched for NUVB on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,765,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders36.09% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvation Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.31) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nuvation Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Nuvation Bio Stock (NYSE:NUVB)Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More NUVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVB Stock News HeadlinesJuly 25 at 9:41 AM | markets.businessinsider.comBuy Rating Backed by Taletrectinib’s Promising Clinical Data and Competitive Edge in NSCLC TreatmentJuly 23, 2024 | businesswire.comNuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, TaletrectinibJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nuvation Bio Amid Promising Taletrectinib Trials and Orphan Drug DesignationJuly 19, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)July 17, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Nuvation Bio (NYSE:NUVB)June 20, 2024 | seekingalpha.comNuvation Bio: A Potentially Transformative AcquisitionJune 2, 2024 | prnewswire.comInnovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual MeetingJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 1, 2024 | prnewswire.comInnovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual MeetingJune 1, 2024 | businesswire.comNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingMay 29, 2024 | businesswire.comNuvation Bio to Present at the Jefferies Global Healthcare ConferenceMay 15, 2024 | markets.businessinsider.comBuy Rating Justified by Nuvation Bio’s Promising Drug Prospects and Strong FinancialsMay 14, 2024 | msn.comNUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024May 14, 2024 | finance.yahoo.comNuvation Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 3, 2024 | investing.comNuvation Bio Inc (NUVB)April 24, 2024 | businesswire.comNuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 17, 2024 | benzinga.comNuvation Bio Stock (NYSE:NUVB), Analyst Ratings, Price Targets, PredictionsSee More Headlines Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+76.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-11.31% Return on Assets-10.99% Debt Debt-to-Equity RatioN/A Current Ratio38.58 Quick Ratio38.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book1.35Miscellaneous Outstanding Shares247,171,000Free Float157,967,000Market Cap$921.95 million OptionableOptionable Beta1.40 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. David T. Hung M.D. (Age 66)Founder, President, CEO & Director Comp: $1MDr. Gary Hattersley Ph.D. (Age 57)Chief Scientific Officer Comp: $694.56kDr. David Liu M.D. (Age 54)Ph.D., Chief Medical Officer Comp: $677.15kMr. Moses Makunje CPA (Age 45)VP of Finance and Principal Accounting & Financial Officer Ms. Stacy Markel (Age 59)Chief People Officer Dr. David C. Hanley Ph.D. (Age 54)Chief Technical Operations Officer Comp: $586.04kMs. Kerry A. Wentworth (Age 51)Chief Regulatory Officer Ms. Colleen Sjogren (Age 54)Chief Commercial Officer Dr. Junyuan Wang Ph.D. (Age 51)CEO & Co-Founder of AnHeart Therapeutics and Director More ExecutivesKey CompetitorsACADIA PharmaceuticalsNASDAQ:ACADMoonLake ImmunotherapeuticsNASDAQ:MLTXMorphicNASDAQ:MORFMorphoSysNASDAQ:MORBausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 157,511 shares on 7/26/2024Ownership: 0.254%SG Americas Securities LLCSold 18,710 shares on 7/12/2024Ownership: 0.013%Xiangmin CuiBought 336,874 shares on 6/24/2024Total: $1.00 M ($2.98/share)Xiangmin CuiBought 87,715 shares on 6/20/2024Total: $262,267.85 ($2.99/share)Kim D BlickenstaffBought 172,189 shares on 6/11/2024Total: $499,348.10 ($2.90/share)View All Insider TransactionsView All Institutional Transactions NUVB Stock Analysis - Frequently Asked Questions How have NUVB shares performed this year? Nuvation Bio's stock was trading at $1.51 at the beginning of 2024. Since then, NUVB stock has increased by 147.0% and is now trading at $3.73. View the best growth stocks for 2024 here. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Who are Nuvation Bio's major shareholders? Top institutional shareholders of Nuvation Bio include Bank of New York Mellon Corp (0.25%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Fund V LP Omega, Oleg Nodelman and Xiangmin Cui. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NUVB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
